Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04976231 · ClinicalTrials.gov registry record
MPS II Immunophenotyping
A clinical trial, sponsored by Duke University.
- Terminated
- Registry status
- 6
- Enrollment target
NCT04976231: Clinical Trial study, sponsored by Duke University.
NCT04976231 is a clinical trial that was terminated before completion, run by Duke University. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04976231 was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate how participant's body's immune system responds to idursulfase, an enzyme replacement therapy (ERT) and find out which types of immune cells are involved in causing untoward responses to the ERT so that the investigators can relate the level of immune response to the treatment.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2022-04-01 |
| Est. Completion | 2024-04-26 |
Why NCT04976231 stopped before completion
NCT04976231 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 6 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04976231 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04976231 about?
NCT04976231 is a clinical study titled "MPS II Immunophenotyping". The purpose of this study is to investigate how participant's body's immune system responds to idursulfase, an enzyme replacement therapy (ERT) and find out which types of immune cells are involved in causing untoward responses to the ERT so that the investigators can relate the level of immune resp...
What is the current status of trial NCT04976231?
This trial is currently terminated. The enrollment target is 6 participants. The study started on 2022-04-01. Estimated completion is 2024-04-26.
Who is sponsoring clinical trial NCT04976231?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI